Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Interventional × Genetic Counseling × Clear all

Phase

Status

Completed 8 Recruiting 5 Unknown 1 Suspended 1 Not yet recruiting 1 Enrolling by invitation 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Cancer Risk Syndrome 1

Interventions

pembrolizumab 375 Carboplatin 268 Cyclophosphamide 264 Nivolumab 256 Paclitaxel 214 Specimen Handling 203 Cisplatin 203 Magnetic Resonance Spectroscopy 201 Radiotherapy 180 Dexamethasone 160 Gemcitabine 154 durvalumab 153 Biopsy 142 atezolizumab 135 Lenalidomide 123 Rituximab 118 Doxorubicin 118 Docetaxel 116 Bevacizumab 116 Ipilimumab 112 Oxaliplatin 102 Capecitabine 102 Radiation 100 fludarabine 98 Radiosurgery 98 Fluorouracil 97 Etoposide 95 venetoclax 94 Prednisone 93 Pemetrexed 90

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04323774 2025-12-12

AYA-RISE

Dana-Farber Cancer Institute

Phase NA Active not recruiting

Cancer Risk Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡